Resources
7 Results (showing 1 - 7)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 4/5/2024
This study assessed the associations between insurance status and 6-month retention of patients with opioid use disorder on telehealth platforms. Patients whose insurance paid for their care were most likely to still be receiving buprenorphine 6 months after starting treatment. Uninsured patients who paid cash were more likely to be in treatment at 6 months than people with insurance that did not cover their care. Findings showed an association between in-network insurance benefits and retention, which may affect the opioid crisis.
Posted 12/3/2019 (updated 3/28/2024)
Billing Behavioral Health Medicaid Services Under Managed Care in New York State.
Posted 6/16/2020 (updated 3/28/2024)
This cross-sectional study included all counties and county-equivalent divisions in the US in 2016. Data on racial/ethnic population distribution were derived from the American Community Survey, and data on locations of facilities providing methadone and buprenorphine were obtained from Substance Abuse and Mental Health Services Administration databases.
Posted 5/11/2020 (updated 3/28/2024)
This fact sheet describes changes to Oregon Health Authority (OHA) reimbursement for Medication-Assisted Treatment drugs administered to fee-for-service Oregon Health Plan members, effective January 1, 2019.
Posted 5/11/2020 (updated 3/28/2024)
Medication assisted treatment (MAT) will be offered to patients who have a current diagnosis of opioid use disorder (OUD), moderate to severe, and who meet predetermined criteria.
Posted 6/18/2023 (updated 3/28/2024)
This report provides information on the results of the Cherokee Nation Health Services' (CNHS) hepatitis C elimination program 5 years after implementation. The report finds that the program had success with 99% of patients who completed treatment.
Posted 3/29/2023 (updated 3/27/2024)
The study has identified inherited genetic markers that are commonly inherited across addiction disorders, regardless of the substance being used. It also reinforces the role of the dopamine system within substance use disorders. This may help to further understand and implement personalized interventions for people with substance use disorders by taking into account a person's biology, environment, and lived experience.